Friday, March 20, 2015 1:05:06 PM
UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility
Benzinga
By Dwight Einhorn 2 hours ago
In a report published Friday, MLV & Co analyst Vernon T. Bernardino initiated coverage on Rexahn Pharmaceuticals, Inc. (NYSE: RNN) with a Buy rating and $1.25 price target.
In the report, MLV & Co noted, "We initiate coverage of Rexahn Pharmaceuticals Inc. (RNN) with a BUY rating and $1.25 PT. We believe investors undervalue Rexahn's clinical-stage oncology assets, which have demonstrated activity in multiple tumor types. We anticipate Rexahn will out-license commercialization of each asset in 1-2 types of cancer, with revenue streams from each worth $0.10- $0.25/sh, and upside potential with advancement in at least 1-2 other cancers ($0.10-$0.50/sh). As a result, we believe the premium valuations ascribed to other oncology-focused companies (EV of $285MM), whose assets we note do not have the broad activity of Rexahn's compounds, should be extended to Rexahn.
"Thus, using DCF analysis, we believe there is upside to $0.91/sh, and by comparable EV analysis, we look for upside to $1.59/sh, which we averaged to $1.25/sh. Lastly, we believe the overhang of a near-term capital raise now passed. With $36MM in cash and our forecast for $34MM in OpEx through 2017, we believe the material risk of shareholder dilution minimal. Therefore, with multiple catalysts anticipated through 2015, we believe current prices offer attractive entry points and would be buyers of the stock."
Rexahn Pharmaceuticals closed on Thursday at $0.70.
Latest Ratings for RNN
Date Firm Action From To
Mar 2015 MLV & Co Initiates Coverage on Buy
Sep 2014 Laidlaw & Co. Initiates Coverage on Buy
Mar 2014 Brinson Patrick Initiates Coverage on Outperform
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM